Larvol Delta - TROPIONLung10-Phase-III-Openlabel-Study-of-Firstline-DatoDXd-in-Combination-With-Rilvegostomig-for-Advanced-Nonsquamous-NSCLC-With-High-PDL1-Expression-TC--50-and-Without-Actionable-Genomic-Alterations

Datroway (datopotamab deruxtecan-dlnk) - Daiichi Sankyo, AstraZeneca

rilvegostomig (AZD2936) - AstraZeneca

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT06357533

Mar 17, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next